Project Grant K01DA060092
- This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $206,180 to the University of California, San Francisco (UCSF) to investigate the complex intersection of HIV, methamphetamine use, and immune dysfunction. The overarching goal is to apply advanced statistical and computational methods to examine the causal relationships between methamphetamine exposure and immune dysfunction, quantify the pharmacologic effects...
- This Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research on the interaction between methamphetamine use and HIV persistence. The $804,728 award to the Regents of the University of California at Riverside will investigate how methamphetamine engages the cysteinyl leukotriene (cysLT)-cysLT receptor 1 (cysLTR1) axis to promote HIV infection, persistence, and brain injury, even in the presence...
- This $616,372 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to identify the role of transposable elements (TEs) in the neurological impacts of HIV, antiretroviral therapy (ART), and cannabis use among people living with HIV-1. The research will leverage single-cell and single-nuclei genomic data from a non-human primate HIV model, postmortem human brain tissues, and a human brain organoid...
- The Project Grant award titled "In Vivo Imaging and Post-Mortem Study of Methamphetamine Use on Immune Dysfunction and HIV Reservoir Transcription Among People with HIV on ART" is funded by the National Institute on Drug Abuse (NIDA) under the federal grant program "Drug Use and Addiction Research Programs" (CFDA 93.279). The $4,663,474 award will support a research project by The Regents of the University of California, San Francisco (UCSF) to study the impact of...
- This is a $2,177,199 project grant awarded by the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), to the J. David Gladstone Institutes in San Francisco, California. The grant aims to develop a novel mouse model that incorporates human microglia, neurons, and astrocytes, derived from induced pluripotent stem cells, to study the impact of HIV and addictive substances on the central nervous system. The project will establish a robust,...
- This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $1,550,462 to support a 5-year cross-sectional, longitudinal, and observational study investigating the impact of Alzheimer's disease (AD) risk genes, with a focus on APOE E4, on brain function in older Black/African American individuals living with HIV. The project aims to enroll 120 participants with HIV (60 with and 60 without the APOE E4 allele) and 80 demographically...
- This federal Project Grant award of $712,500 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the impact of MDMA and methamphetamine on the visual and associative regions of the macaque monkey brain. The research will use electrophysiology and deep neural networks to determine how social viewing affects drug-taking and integration, hypothesizing that positive social stimulation reduces drug-taking impulses....
- This federal Project Grant award of $439,180.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to "DECONVOLUTE DOPAMINERGIC NEURONAL-GLIAL INTERACTIONS IN THE STRIATUM" at The Johns Hopkins University. The research aims to investigate how HIV replication and methamphetamine exposure impact dopaminergic neuron-glial communication in the brain, focusing on the role of the mTOR-OPN/SPP1 signaling pathway....
- This $629,712 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to conduct research on "GLYMPHATIC MR IMAGING AND BIOMARKER DISCOVERY IN AGING WITH HIV INFECTION". The grant aims to utilize MRI imaging techniques to better understand how the brain's waste clearance system, known as the glymphatic system, is impacted by aging and HIV infection. This research seeks to identify potential biomarkers that could...
- The National Institutes of Health (NIH), through the Mental Health Research Grants program (CFDA 93.242) administered by the National Institute of Mental Health (NIMH), has awarded a $434,500 R21 grant to the University of California, San Diego (UCSD) to investigate the epigenetic mechanisms controlling HIV latency and neuropathogenesis in microglia. The project aims to use single-cell multi-omics approaches and state-of-the-art sequencing technologies to characterize the transcriptomic and...
BRAIN AGE OF PEOPLE WITH HIV AND HISTORY OF METHAMPHETAMINE USE - PROJECT SUMMARY NEUROIMAGING STUDIES SHOW A RELATIONSHIP BETWEEN ACCELERATED BIOLOGICAL AGING AND ACCELERATED BRAIN ATROPHY EVEN IN HEALTHY POPULATIONS. RECENT MACHINE LEARNING APPROACHES HAVE USED NEUROIMAGING VARIABLES, SUCH AS CORTICAL THICKNESS AND SUBCORTICAL VOLUME, TO CALCULATE AN ESTIMATED "BRAIN AGE" AS A MEASURE OF BIOLOGICAL AGING. ESTIMATED BRAIN AGE GREATER THAN AN INDIVIDUAL'S CHRONOLOGICAL AGE IS THOUGHT TO REFLECT AN ACCELERATED RATE OF AGE-RELATED CHANGES TO THE BRAIN AND MAY PREDICT FUTURE IMPAIRMENTS IN COGNITIVE FUNCTIONING. ACCELERATED BIOLOGICAL BRAIN AGING MAY OCCUR AMONG PEOPLE WITH HIV (PWH), AS CENTRAL NERVOUS SYSTEM COMPLICATIONS FROM HIV INFECTION MAY OCCUR EVEN IN INDIVIDUALS TAKING ANTIRETROVIRAL THERAPY (ART). METHAMPHETAMINE (METH) USE, WHICH IS COMMON AMONG PWH, MAY ALSO BE DETRIMENTAL TO BRAIN HEALTH. IT IS HYPOTHESIZED THAT METH'S EFFECTS ON THE CENTRAL NERVOUS SYSTEM MAY HAVE A SYNERGISTIC EFFECT ON THE LONG-TERM IMPACT OF HIV INFECTION. THIS K01 APPLICATION WILL USE STRUCTURAL AND FUNCTIONAL NEUROIMAGING MEASURES TO DEVELOP A NORMATIVE MODEL OF BRAIN AGE USING DATA FROM THE HUMAN CONNECTOME PROJECT TO LEVERAGE HYPOTHESIS TESTING IN A LOCALLY COLLECTED DATASET BY THE UC SAN DIEGO TRANSLATIONAL METHAMPHETAMINE AIDS RESEARCH CENTER (TMARC) THAT INCLUDES ADULTS STRATIFIED BY HIV INFECTION AND METHAMPHETAMINE USE. SPECIFIC AIM 1 WILL ESTIMATE BRAIN AGE IN THE TMARC COHORT USING A COMPOSITE MEASURE OF CORTICAL THICKNESS AND SUBCORTICAL VOLUME DERIVED FROM T1-WEIGHTED STRUCTURAL SCANS AND COMPARE IT TO CHRONOLOGICAL AGE AND COGNITIVE MEASURES. WE HYPOTHESIZE THAT HIV INFECTION AND METH USE WILL INDIVIDUALLY ACCELERATE BRAIN AGE, BUT THAT THEIR COMBINED EFFECTS WILL BE ASSOCIATED WITH GREATER ACCELERATED AGING. SPECIFIC AIM 2 WILL INTEGRATE T1-WEIGHTED AND RESTING-STATE FUNCTIONAL NEUROIMAGING SCANS TO DEVELOP A BRAIN-AGE MODEL BASED ON MULTI-MODAL NEUROIMAGING DATA WHICH IS HYPOTHESIZED TO BE MORE SENSITIVE TO THE EFFECTS OF METH USE AND HIV STATUS ON BRAIN AGE AND COGNITIVE MEASURES. SPECIFIC AIM 3 WILL INVESTIGATE WHETHER INFLAMMATION INDEXED BY CRP, MCP-1 AND NFL FROM CEREBROSPINAL FLUID HAS AN INDIRECT EFFECT ON THE ASSOCIATION BETWEEN BRAIN AGE AND HISTORY OF METH USE OR BETWEEN BRAIN AGE AND HIV STATUS. DISENTANGLING THE BIOLOGICAL EFFECTS OF HIV IN OLDER ADULTS AND ITS RELATION TO HISTORY OF METH USE WILL ADVANCE THE HIV FIELD THROUGH INFORMING OUR UNDERSTANDING OF HOW BIOMARKERS OF NEURAL INTEGRITY AND INFLAMMATION RELATED TO COGNITION, WHICH MAY INFORM FUTURE HEALTH INTERVENTIONS. THIS K01 APPLICATION HAS BROAD, LONG-TERM OBJECTIVES THAT INCLUDE OBTAINING EXPERIENCE IN DATA-SCIENCE METHODOLOGIES USING NEUROIMAGING DATA IN ORDER TO GENERATE MODELS THAT WILL PUSH NEUROIMAGING RESEARCH TOWARDS MORE CLINICAL APPLICATIONS IN SUBSTANCE USE AND HIV INFECTION. THIS PROPOSED K01 PROJECT WILL PROVIDE THE APPLICANT WITH CRITICAL TRAINING IN DATA SCIENCE USING NEUROIMAGING DATA, WHICH WILL BROADEN HER RESEARCH SKILL-SET AND PROVIDE PRELIMINARY FINDINGS FOR THE PREPARATION OF AN R-LEVEL APPLICATION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $180.2k | 4/30/25 | ||
| Not listed | $0 | 5/29/24 | ||
| Not listed | $0 | 5/29/24 | ||
| Not listed | $159.1k | 5/8/24 | ||
| Not listed | $159.1k | 5/8/24 |